Associate Professor
University of Texas MD Anderson Cancer Center
Bellaire, TX, United States
Nitin Jain, M.D., is an Associate Professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center (MDACC) in Houston, Texas, USA. Dr. Jain treats patients with acute and chronic leukemias with focus of patients with chronic lymphocytic leukemia (CLL) and acute lymphoblastic leukemia (ALL). Since 2021, he has also served as Director, Cellular Therapy Program within the Department of Leukemia, MDACC. Dr. Jain is Principal Investigator of several investigator-initiated phase I-II clinical trials, including combination targeted therapies (ibrutinib and venetoclax) in CLL, checkpoint inhibitor in Richter transformation, JAK2 inhibitor ruxolitinib in Ph-like ALL, novel CD22 antibody drug conjugate in B-ALL, venetoclax + chemotherapy in B- and T-ALL, ponatinib in T-ALL, and off-the-self allogeneic CARTs in B-ALL. He has published papers in prominent journals including NEJM, JAMA Oncology, Journal of Clinical Oncology, Blood, Clinical Cancer Research, Cancer, Leukemia & Lymphoma, and others. He has won many awards during his career including Sardari Lal Kalra Gold Medal in Microbiology from AIIMS and Merit Award from the American Society of Clinical Oncology (ASCO). He received High-Impact Clinical Research Support Award from MD Anderson Cancer Center in the year 2014 and 2016. He has served as faculty on American Society of Hematology CRTI workshop from 2017-2019. He is recipient of Sabin Family Foundation Award in 2018. In 2020, he received MD Anderson Faculty Scholar award. In 2021, he was appointed Director of the CAR-T program for the Leukemia Department, MDACC. In 2022, he received Leukemia and Lymphoma Society (LLS) Career Development Program (CDP) Award as well as LLS Translational Research Program (TRP) award.
Friday, October 6, 2023
10:45 AM – 10:55 AM EDT
Current and Future Use of BTKi + BCL-2i Combinations
Sunday, October 8, 2023
8:45 AM – 9:00 AM EDT
